Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma

Nature Genetics

Volumn 48, Issue 6, 2016, Pages 675-680

  Moore, Amanda R ^a,b   Ceraudo, Emilie ^c   Sher, Jessica J ^a   Guan, Youxin ^a   Shoushtari, Alexander N ^a,d   Chang, Matthew T ^a,e   Zhang, Jenny Q ^a   Walczak, Edward G ^a   Kazmi, Manija A ^c   Taylor, Barry S ^a   Huber, Thomas ^c   Chi, Ping ^a,b,d   Sakmar, Thomas P ^c,f   Chen, Yu ^a,b,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINYL LEUKOTRIENE RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; GLUTAMINE; GNA11 PROTEIN; GNAQ PROTEIN; LEUCINE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; PHORBOL ESTER; PLCB4 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; CALCIUM;

ARTICLE; CARCINOGENESIS; CELL LINEAGE; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOSOME; NONHUMAN; PRIORITY JOURNAL; UVEA MELANOMA; ANIMAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEK293 CELL LINE; MELANOMA; METABOLISM; MOUSE; MUTATION; SCID MOUSE; UVEA TUMOR;

ANIMALS; CALCIUM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEK293 CELLS; HUMANS; MELANOMA; MICE; MICE, SCID; MUTATION; RECEPTORS, LEUKOTRIENE; UVEAL NEOPLASMS;

EID: 84964334407     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3549     Document Type: Article

References (38)

1. Van Raamsdonk, C.D., et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602 (2009
2. Van Raamsdonk, C.D., et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199 (2010
3. Johansson, P., et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 7, 4624-4631 (2016
4. Furney, S.J., et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 3, 1122-1129 (2013
5. Martin, M., et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933-936 (2013
6. Chang, M.T., et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155-163 (2016
7. Leiserson, M.D., Wu, H.T., Vandin, F., & Raphael, B.J. CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome Biol. 16, 160 (2015
8. Harbour, J.W., et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413 (2010
9. Harbour, J.W., et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45, 133-135 (2013
10. Evans, J.F. Cysteinyl leukotriene receptors. Prostaglandins Other Lipid Mediat. 68-69, 587-597 (2002
11. Sakmar, T.P. Structure of rhodopsin and the superfamily of seven-helical receptors: the same and not the same. Curr. Opin. Cell Biol. 14, 189-195 (2002
12. Ballesteros, J.A., & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. in Methods in Neurosciences Vol. 25 (ed. Stuart, C.S) 366-428 (Academic Press, 1995
13. Tao, Y.X. Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol. Ther. 120, 129-148 (2008
14. Zhang, C., et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492, 387-392 (2012
15. Bennett, D.C., Cooper, P.J., & Hart, I.R. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int. J. Cancer 39, 414-418 (1987
16. Prince, S., Wiggins, T., Hulley, P.A., & Kidson, S.H. Stimulation of melanogenesis by tetradecanoylphorbol 13-acetate (TPA) in mouse melanocytes and neural crest cells. Pigment Cell Res. 16, 26-34 (2003
17. Yaar, M., & Gilchrest, B.A. Human melanocyte growth and differentiation: a decade of new data. J. Invest. Dermatol. 97, 611-617 (1991
18. Griewank, K.G., et al. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res. 25, 182-187 (2012
19. Parma, J., et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365, 649-651 (1993
20. Liu, G., et al. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N. Engl. J. Med. 341, 1731-1736 (1999
21. Kan, Z., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010
22. Prickett, T.D., et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 43, 1119-1126 (2011
23. Kandoth, C., et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013
24. Lawrence, M.G., et al. A preclinical xenograft model of prostate cancer using human tumors. Nat. Protoc. 8, 836-848 (2013
25. Garraway, L.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005
26. Leff, J.A., et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. 339, 147-152 (1998
27. Wunder, F., et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor. Br. J. Pharmacol. 160, 399-409 (2010
28. Bond, R.A., & Ijzerman, A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 27, 92-96 (2006
29. Langmead, B., & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012
30. Li, H., et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009
31. Robinson, J.T., et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011
32. Cerami, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012
33. Cheng, D.T., et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251-264 (2015
34. Refaeli, Y., Van Parijs, L., Alexander, S.I., & Abbas, A.K. Interferon ? is required for activation-induced death of T lymphocytes. J. Exp. Med. 196, 999-1005 (2002
35. Leduc, M., et al. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J. Pharmacol. Exp. Ther. 331, 297-307 (2009
36. Martí-Renom, M.A., et al. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29, 291-325 (2000
37. Larkin, M.A., et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948 (2007
38. Humphrey, W., Dalke, A., & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38, 27-28 (1996